Lyme disease is becoming a larger public health concern as ticks expand their range, seasons of activity grow longer and scientists search for better ways to prevent infections. In the United States, an estimated 476,000 cases of Lyme disease are diagnosed and treated each year, yet there is currently no FDA-approved vaccine or preventive drug for people.

That could change. Pfizer and Valneva’s experimental Lyme disease vaccine has produced more than 70% efficacy in a Phase 3 trial, while other researchers are developing different approaches that could prevent infection without requiring a conventional vaccine.

The need for new prevention strategies is becoming more pressing. Lyme disease is caused by Borrelia bacteria transmitted through the bites of infected ticks. Early symptoms can include fever, chills, body aches and the characteristic expanding rash associated with some infections. When untreated, the disease can lead to more serious problems involving the nervous system, joints and other parts of the body.

For people who spend time outdoors, the risk can be difficult to avoid completely. Ticks can be encountered in forests, tall grass and even residential yards. Pets can also carry ticks into homes, creating another potential route of exposure.

The challenge for scientists is therefore not simply developing another treatment for Lyme disease. It is finding a practical way to stop infection before the bacteria become established in the human body.

Lyme disease vaccine research reaches a critical stage

The most advanced candidate is PF-07307405, developed by Pfizer and Valneva. The experimental vaccine targets outer surface protein A, or OspA, which is found on the surface of Borrelia burgdorferi, one of the bacteria responsible for Lyme disease.

The strategy is unusual because the vaccine can begin working against the bacteria while they are still inside the tick.

After vaccination, the person’s immune system produces antibodies against several versions of OspA. When an infected tick begins feeding, it consumes some of the person’s blood along with those antibodies. The antibodies can then bind to OspA inside the tick and interfere with the bacteria before they can leave the tick and enter the person.

“It’s a good time for there to be a new preventative,” said Thomas Hart, assistant professor of molecular microbiology and immunology at Johns Hopkins Lyme and Tickborne Diseases Research and Education Institute.

Pfizer and Valneva announced Phase 3 results in March 2026 from a trial involving more than 9,400 participants. The four-dose regimen was more than 70% effective at preventing Lyme disease.

The result was encouraging, but the trial produced fewer Lyme disease cases than researchers had anticipated. That limited the statistical strength of the findings and meant the results were not as conclusive as the developers had hoped.

The companies reported no major safety concerns and said they planned to submit the vaccine to regulators.

The candidate also has an important historical comparison. The United States previously had a Lyme disease vaccine called LYMErix, which was approved in 1998 after a trial involving more than 10,000 people. It demonstrated 76% efficacy in preventing Lyme disease.

However, demand for LYMErix remained low. Reports and lawsuits alleging side effects, particularly arthritis, contributed to concerns surrounding the vaccine. Federal health officials reviewed the available data in 2002 and found no evidence of a safety risk, but the manufacturer discontinued the product that year, citing insufficient demand.

The history of LYMErix remains relevant because developing an effective vaccine is only part of the challenge. Any new vaccine must also overcome questions about safety, public confidence, dosing and whether people will seek vaccination before spending time in areas where infected ticks are common.

The field has expanded beyond Pfizer and Valneva. Moderna is testing two Lyme disease vaccine candidates, mRNA-1975 and mRNA-1982, which are also aimed at OspA. Both candidates are in Phase 2 development. Moderna’s development pipeline lists the two Lyme vaccine programs alongside its other infectious-disease vaccine research.

Researchers at Yale University are pursuing another strategy: a vaccine designed to stimulate an immune response to tick saliva rather than directly targeting the Lyme bacteria. The approach remains experimental and has not yet been tested in humans.

That reflects the broader direction of Lyme disease research. Scientists are increasingly looking beyond a single vaccine formula and examining whether infection can be prevented by interfering with the bacteria, the tick or the interaction between the two.

Scientists are testing antibodies and anti-tick drugs

A Lyme disease vaccine is not the only possible solution. Another approach is passive immunity, in which people receive antibodies directly rather than being vaccinated and waiting for their immune systems to produce them.

Mark Klempner, a professor of medicine at UMass Chan Medical School, has spent more than a decade developing such an approach. The experimental treatment, known as TNX-4800, is a long-acting monoclonal antibody designed to target OspA.

Instead of teaching the immune system to make antibodies, the injection supplies them directly. Researchers are investigating whether a dose given around the beginning of tick season could provide protection for months.

That could be particularly useful in regions where Lyme disease is common but not necessarily present everywhere that ticks are found. In parts of the southeastern United States, for example, Lyme disease is relatively uncommon because the local tick ecology differs from that of regions where transmission is more established.

TNX-4800 has completed Phase 1 testing. Tonix Pharmaceuticals, which licensed the program in 2025, is preparing an adaptive Phase 2 field study, pending agreement with the FDA. Tonix’s TNX-4800 program describes the treatment as an investigational monoclonal antibody for seasonal prevention of Lyme disease.

A different strategy could eliminate the need to target the bacteria altogether.

Tarsus Pharmaceuticals is developing TP-05, an oral drug based on an ingredient already used as an anti-tick treatment for dogs. Rather than preventing infection by activating human immunity, the drug is designed to kill ticks after they begin feeding.

The underlying idea is straightforward: if a tick dies quickly enough, it may not survive long enough to transmit Lyme disease bacteria or other pathogens.

The approach could have implications beyond Lyme disease. Ticks transmit several infections, including babesiosis and anaplasmosis. A treatment that acts directly on ticks could therefore potentially reduce exposure to multiple pathogens rather than targeting a single bacterium.

However, these products remain investigational. None should be considered an approved replacement for established tick-bite prevention.

The difficulty of developing such products also explains why progress has taken years. Human Lyme disease trials require large populations followed over extended periods because researchers cannot simply expose participants to infected ticks to guarantee that enough infections occur for a study to measure effectiveness.

Animal studies can use controlled tick exposure, making them more straightforward. Human challenge studies raise obvious ethical concerns because researchers would intentionally expose people to a pathogen that can sometimes cause persistent health problems.

As a result, scientists must wait for natural exposure to produce enough infections among study participants. That makes trials slower, more expensive and more difficult to design.

Why tick prevention still matters

The growing pipeline of Lyme disease vaccines and preventive treatments does not eliminate the need to avoid tick bites.

The Centers for Disease Control and Prevention estimates that about 476,000 people in the United States are diagnosed and treated for Lyme disease each year. The agency identifies avoiding tick bites as the best defense against the disease. CDC guidance on preventing Lyme disease recommends avoiding areas with tall grass, brush and dense vegetation when possible, using appropriate insect repellents, wearing protective clothing and checking the body and pets for ticks.

Climate and ecological changes are making that prevention challenge harder. Tick populations are expanding in parts of Europe and the United States, while milder winters can extend the period during which ticks remain active.

Ticks also carry pathogens other than those responsible for Lyme disease. That means reducing tick exposure can protect against several illnesses at the same time.

For people who own dogs, the contrast can be striking. Veterinarians already have multiple tools for protecting pets from ticks, including topical treatments, collars and oral medications. Dogs can also receive vaccines against Lyme disease.

Humans have considerably fewer options.

That gap is one reason researchers are pursuing several prevention strategies simultaneously. A vaccine could provide long-term immune protection. A monoclonal antibody could offer seasonal protection without requiring the recipient’s immune system to generate antibodies. An oral anti-tick drug could potentially kill ticks before they transmit infection.

Each approach has different advantages and unresolved questions.

For now, practical prevention remains essential. People who have been outdoors in areas where ticks are common can reduce their risk by checking their bodies, clothing and pets after returning inside. Showering soon after outdoor exposure can also help remove unattached ticks, while promptly removing an attached tick can reduce the chance of infection.

The goal of the emerging research is to make prevention less dependent on remembering those precautions every time someone goes outdoors.

“People get tired or are out late at night, the kids are cranky,” said Linden Hu, a professor of immunology at Tufts University School of Medicine who has worked on anti-tick strategies. A vaccine or preventive pill that people can take without having to remember every outdoor exposure, he said, could provide a significant public health benefit.

The science is moving toward that possibility, but the next generation of Lyme disease prevention remains subject to clinical testing and regulatory review.